Review
doi: 10.7774/cevr.2015.4.1.46. Epub 2015 Jan 30.Clinical vaccine development
Affiliations
- PMID:25648742
- PMCID: PMC4313108
- DOI: 10.7774/cevr.2015.4.1.46
Item in Clipboard
Review
Clinical vaccine development
Seunghoon Han. Clin Exp Vaccine Res.2015 Jan.
Display options
Format
Display options
Format
Abstract
Vaccination is regarded as one of the biggest triumphs in the history of medicine. We are living in the most successful period of vaccine development. The accumulation of multidisciplinary knowledge and the investment of massive funding have enabled the development of vaccines against many infectious diseases as well as other diseases including malignant tumors. The paradigm of clinical vaccine evaluation and licensure has also been modernized based on scientific improvements and historical experience. However, there remain a number of hurdles to overcome. Continuous efforts are focused on increasing the efficacy and reducing the risks related to vaccine use. Cutting-edge knowledge about immunology and microbiology is being rapidly translated to vaccine development. Thus, physicians and others involved in the clinical development of vaccines should have sufficient understanding of the recent developmental trends in vaccination and the diseases of interest.
Keywords: Clinical trial; History; Vaccination; Vaccines.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Rise of vaccinology by Hilleman [1].H. influenzae,Haemophilus influenzae.
Current pathway of vaccine development. BLA, Biologic License Application; IND, investigational new drug; M USD, million United States dollars.
Target population for vaccines in the 21st century by Rappuoli et al. [25]. (A) The most important vaccines for each age group are reported. (B) Special target groups for vaccination in the 21st century. The most important vaccines for each target group are reported. The lists of vaccines reported are indicative and are not intended to be exhaustive.C. difficile,Clostridium difficile;E. coli,Escherichia coli; EV71, enterovirus 71;H. influenzae,Haemophilus influenzae;K. pneumoniae,Klebsiella pneumoniae;P. aeruginosa,Pseudomonas aeruginosa;S. aureus,Staphylococcus aureus; AIDS, acquired immune deficiency syndrome; SARS, severe acute respiratory syndrome.
Similar articles
- [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].Pfleiderer M, Wichmann O.Pfleiderer M, et al.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):263-73. doi: 10.1007/s00103-014-2109-y.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015.PMID:25566841German.
- Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.Laupèze B, Hervé C, Di Pasquale A, Tavares Da Silva F.Laupèze B, et al.Vaccine. 2019 Sep 10;37(38):5670-5680. doi: 10.1016/j.vaccine.2019.07.098. Epub 2019 Aug 13.Vaccine. 2019.PMID:31420171Review.
- Principles of Vaccination.Zepp F.Zepp F.Methods Mol Biol. 2016;1403:57-84. doi: 10.1007/978-1-4939-3387-7_3.Methods Mol Biol. 2016.PMID:27076125
- [Frontier of mycobacterium research--host vs. mycobacterium].Okada M, Shirakawa T.Okada M, et al.Kekkaku. 2005 Sep;80(9):613-29.Kekkaku. 2005.PMID:16245793Japanese.
- Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, Levine MM, Maldonado YA, Marcuse EK, Monath TP, Osborn JE, Plotkin S, Poland GA, Quinlisk MP, Smith DR, Sokol M, Soland DB, Whitley-Williams PN, Williamson DE, Breiman RF.Peter G, et al.Pediatrics. 1999 Oct;104(4 Pt 1):942-50.Pediatrics. 1999.PMID:10506239Review.
Cited by
- The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria.Khalid K, Poh CL.Khalid K, et al.Vaccines (Basel). 2023 Jul 20;11(7):1264. doi: 10.3390/vaccines11071264.Vaccines (Basel). 2023.PMID:37515079Free PMC article.Review.
- Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt.Hammam N, Tharwat S, Shereef RRE, Elsaman AM, Khalil NM, Fathi HM, Salem MN, El-Saadany HM, Samy N, El-Bahnasawy AS, Abdel-Fattah YH, Amer MA, ElShebini E, El-Shanawany AT, El-Hammady DH, Noor RA, ElKhalifa M, Ismail F, Fawzy RM, El-Najjar AR, Selim ZI, Abaza NM, Radwan AR, Elazeem MI, Mohsen WA, Moshrif AH, Mohamed EF, Aglan LI, Senara S, Ibrahim ME, Khalifa I, Owaidy RE, Fakharany NE, Mohammed RHA, Gheita TA; Egyptian College of Rheumatology (ECR) COVID-19 Study Group.Hammam N, et al.Rheumatol Int. 2021 Sep;41(9):1607-1616. doi: 10.1007/s00296-021-04941-0. Epub 2021 Jul 9.Rheumatol Int. 2021.PMID:34244818Free PMC article.
- Establishing the safety of selective digestive decontamination within the ICU population: a bridge too far?Hurley JC.Hurley JC.Trials. 2023 May 17;24(1):337. doi: 10.1186/s13063-023-07356-3.Trials. 2023.PMID:37198636Free PMC article.
- A brief outlook on the current emerging trends of COVID 19 vaccines.Smitha T, Thomas A.Smitha T, et al.J Oral Maxillofac Pathol. 2020 May-Aug;24(2):206-211. doi: 10.4103/jomfp.JOMFP_334_20. Epub 2020 Sep 9.J Oral Maxillofac Pathol. 2020.PMID:33456225Free PMC article.No abstract available.
- COVID-19 vaccines: current and future challenges.Mohammadi D, Ghasemi M, Manouchehrian N, Zafarmand M, Akbari M, Boroumand AB.Mohammadi D, et al.Front Pharmacol. 2024 Nov 6;15:1434181. doi: 10.3389/fphar.2024.1434181. eCollection 2024.Front Pharmacol. 2024.PMID:39568586Free PMC article.Review.
References
- Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. J Hum Virol. 2000;3:63–76. - PubMed
- Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife: threats to biodiversity and human health. Science. 2000;287:443–449. - PubMed
- Gostin LO, Lucey D, Phelan A. The Ebola epidemic: a global health emergency. JAMA. 2014;312:1095–1096. - PubMed
- Leung AK. "Variolation" and vaccination in late Imperial China, Ca 1570-1911. In: Plotkin SA, editor. History of vaccine development. New York: Springer; 2011. pp. 5–12.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources